AI Article Synopsis

  • A 76-year-old woman was hospitalized in 2007 for diarrhea and weight loss, leading to the discovery of a tumor in her abdomen through a CT scan.
  • After surgeries which revealed the tumor originated from the transverse colon, she was diagnosed with colorectal neuroendocrine carcinoma and started on FOLFOX4 chemotherapy.
  • Despite recurrent tumors throughout her treatment, a combination therapy of bevacizumab, levofolinate, and 5-FU proved effective, resulting in a complete response by 2010, prompting discussions on treatment strategies for this challenging cancer.

Article Abstract

A 76-year-old woman was admitted to our hospital with diarrhea and weight loss in February 2007. A CT scan revealed a tumor in the abdominal cavity, and although a thorough investigation was conducted, no diagnosis was made. Therefore, she underwent diagnostic surgery in April 2007. Intraoperatively, the tumor was determined to have originated in the transverse colon, with invasion to other organs. The patient underwent a transverse colectomy, partial ileal resection, and partial resection of the bladder and peritoneum were performed. The pathological diagnosis was colorectal neuroendocrine carcinoma. FOLFOX4 chemotherapy was initiated in May 2007. However, a CT scan in June 2007 revealed a recurrent tumor in the right pelvis. Although right hemicolectomy and right oophorectomy were performed in August, a CT scan in September 2007 revealed a recurrent tumor in the right pelvis. Following treatment with bevacizumab+levofolinate+5-FU, the tumor disappeared. The patient continued to receive this chemotherapy regimen until August 2010, and CT scans showed a complete response. Even though colorectal neuroendocrine carcinoma is known to have a poor prognosis, the present case was effectively treated with bevacizumab+levofolinate+5-FU chemotherapy. Herein we provide discussion and suggestions about treatment for colorectal neuroendocrine carcinoma.

Download full-text PDF

Source

Publication Analysis

Top Keywords

colorectal neuroendocrine
16
neuroendocrine carcinoma
16
effectively treated
8
treated bevacizumab+levofolinate+5-fu
8
2007 scan
8
2007 revealed
8
revealed recurrent
8
recurrent tumor
8
tumor pelvis
8
0
5

Similar Publications

The morphologic diagnosis of colorectal carcinoma (CRC) is typically straight forward. However, there are certain subtypes of CRC that pose diagnostic challenges for daily practice due to sometimes overlapping morphologic and immunohistochemical features. These subtypes include poorly differentiated adenocarcinoma NOS, in the absence of conventional morphology (PDA-NOS), large cell neuroendocrine carcinoma (LCNEC), medullary carcinoma (MC), undifferentiated carcinoma (UC) and lymphoepithelioma-like carcinoma (LELC).

View Article and Find Full Text PDF

Objective: Dual-layer spectral detector CT (DLCT) has several advantages in clinical practice, this study aims to reveal the clinical applications of DLCT in digestive system diseases.

Materials And Methods: We searched PubMed and Cochrane Reviews for articles published from January 1, 2010 to May 31, 2024, using the terms "dual-layer spectral detector CT" or "dual-layer CT" combined with "hepatic fat" or "hepatic fibrosis" "hepatocellular carcinoma" or "pancreatic ductal adenocarcinoma" or "pancreatic neuroendocrine tumors" or "gastric cancer" or "colorectal cancer" or "Crohn's disease" or "bowel ischemia" or "acute abdominal conditions".

Results: DLCT consists of a top layer sensitive to lower-energy photons and a bottom layer sensitive to higher-energy photons.

View Article and Find Full Text PDF

Kirsten rat sarcoma viral oncogene homolog (KRAS) somatic mutations occur in 30% to 40% of patients with colorectal cancer (CRC). These were thought to equally affect prognosis and resistance to anti-epidermal growth factor receptor agents; however, recent data show the activity of KRAS-G12C and pan-RAS inhibitors. The effects of uncommon KRAS (uKRAS) variants are largely unexplored.

View Article and Find Full Text PDF

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneousgroup of rare cancers. The effects of micronutrients on GEP-NETs have been explored in observational studies, but with inconsistent results. We conducted a two-sample Mendelian randomization (TSMR) study to investigate whether micronutrients influence the risk of GEP-NETs.

View Article and Find Full Text PDF
Article Synopsis
  • There has been a concerning rise in early-onset colorectal cancer (EO-CRC) cases, prompting research into how prognosis compares to late-onset colorectal cancer (LO-CRC).
  • A systematic review of 26 studies found that EO-CRC patients are more likely to be diagnosed at advanced stages, yet they have better overall survival rates compared to LO-CRC patients, while other survival metrics like cancer-specific survival remain similar.
  • The study highlights the need for better early detection methods for EO-CRC due to the differences in stage at diagnosis between the two groups.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!